Publications by authors named "D V Lavrnic"
Genome-wide association studies (GWAS) have provided strong evidence that early- and late-onset MG have different genetic backgrounds. Recent in silico analysis based on GWAS results revealed rs231735 and rs231770 variants within CTLA-4 locus as possible MG causative genetic factors. We aimed to explore the association of rs231735 and rs231770 with MG in a representative cohort of Serbian patients.
View Article and Find Full Text PDFGalactosylation of serum immunoglobulin G in myasthenia gravis with different autoantibodies.
Scand J Clin Lab Invest
September 2023
Myasthenia gravis (MG) is a disease with impaired transmission at the neuromuscular junction, characterised by weakness and fatigability of skeletal muscles. In acquired autoimmune MG, antibodies against acetylcholine receptor (AChRAb) or muscle-specific tyrosine kinase (MuSKAb) are present. There is not much data about immunoglobulin G (IgG) galactosylation in MG, and none based on interactions with lectins.
View Article and Find Full Text PDFArticle Synopsis
- Myasthenia gravis (MG) is an autoimmune disease leading to muscle weakness, and the study aimed to assess COVID-19 infection rates and vaccination status among MG patients.
- Among 125 MG patients studied, one-third contracted COVID-19, with severe cases more likely in older individuals with existing health issues, while 21% experienced worsening of MG symptoms post-infection.
- Almost 70% of the MG patients were vaccinated against SARS-CoV-2, primarily with Sinopharm and Pfizer-BioNTech, though 36% reported adverse reactions, mostly mild flu-like symptoms.
Introduction: Severe myasthenia gravis (MG) exacerbation with respiratory failure and/or dysphagia usually requires monitoring and treatment in the neurology intensive care unit (NICU). The aim of our study was to identify all patients with severe MG exacerbation treated in the NICU in order to assessed potential factors affecting patients' need for mechanical ventilation, occurrence of complications and the final outcome.
Methods: We retrospectively included all patients with severe exacerbation of MG who required management in the NICU during a 14-year period.
Introduction: Even treated, myasthenia gravis (MG) continues to represent a significant burden and might continuously affect patients' quality of life (QoL). The aim of our longitudinal study was to analyze QoL in a large cohort of MG patients after a 10-year follow-up period.
Methods: This study comprised 78 MG patients (60% females, 50 ± 16 years old at baseline, 70% AchR positive) who were retested after 10 years.